Navigation Links
Unraveling the complex signaling that helps cells know when to grow, when to sit tight

BOSTON -- Even yeast understand austerity. A finely tuned system evolved early on to help cells survive in a world where good times come as fast as they go. The system, a molecular switch found in organisms from yeast to humans, involves a nutrient-sensing protein that turns growth on in times of plenty and shuts it off when times are lean.

New work from the lab of Wenyi Wei, PhD, an investigator in the Department of Pathology at Beth Israel Deaconess Medical Center and J. Wade Harper, PhD, of the Department of Cell Biology at Harvard Medical School (HMS), has uncovered the mechanism that flips this switch. They found that mTOR, the mammalian version of this key protein, turns itself on in a positive feedback loop involving destruction of DEPTOR, the protein that holds the mTOR switch in the off position.

The results are reported in the Oct. 20 online edition of Molecular Cell along with two other papers reporting similar findings.

The mTOR pathway has been linked to cancer in cases where an abnormality in the signaling allows cells to grow uncontrollably regardless of fitness, so complete understanding of the intricacies of mTOR signaling could contribute to the design of novel cancer treatments. The pathway has also been linked to cardiovascular, autoimmune and metabolic diseases. This new work answers key questions about how the switch flips but also raises intriguing new questions about how an inactivated protein can activate itself.

When Wei, Assistant Professor of Pathology at HMS, began this investigation, parts of the mTOR switch mechanism had already been uncovered. For instance, DEPTOR holds mTOR in the off position by binding with it and blocking its activity. Further, DEPTOR vanishes through ubiquitination, a process that tags proteins for destruction and sends them to the proteasome, a disposal system that shreds proteins when they are no longer needed.

But the molecular mechanism that triggers DEPTOR to vanish was unknown. Wei, an expert in ubiquitination, decided to take on the problem.

To find out which protein(s) signals DEPTOR to degrade, the investigators employed a technology called ComPASS developed by Harper, the Bert and Natalie Vallee Professor of Molecular Pathology at HMS. Developed in 2009, ComPASS specifically identifies protein interactions and protein complexes.

In the case of DEPTOR, Wei and Harper found that the E3 ligase beta-TrCP marks DEPTOR for disposal by tagging it with ubiquitins. This tagging causes DEPTOR to be rapidly depleted, unleashing mTOR and, in turn, cell growth.

But beta-TrCP only tags DEPTOR if it has been phosphorylated, a process that marks a protein with phosphates to activate or deactivate it. So, asked Wei, how does DEPTOR get phosphorylated?

In a screening process to identify the proteins responsible for phosphorylatingand therefore depletingDEPTOR, he found two culprits: casein kinase 1 (CK1) and mTOR. "We were really surprised to find mTOR itself degrading DEPTOR," says Wei. "In a starvation state, DEPTOR levels are high and mTOR should not be able to do anything."

But when nutrients come in, something changes. With the deftness of Houdini, mTOR escapes from DEPTOR's binds and springs into action. The first thing mTOR does is join with CK1, a helper protein kinase that is always waiting around on standby. Together, mTOR and CK1 phosphorylate DEPTOR, triggering a rapid ubiquitination response from beta-TrCP and the immediate degradation of DEPTOR.

It is this mysterious feat that has now has Wei's attention. "How can mTOR be activated when it is fully suppressed by DEPTOR? We really want to know that," he says. The team is actively examining this question.

While this signaling pathway originally evolved as a nutrient sensor, in more complex organisms it acts as a fitness sensor. "All sorts of stimuli are integrated into one circuit," says Bing Su, Associate Professor of Immunobiology at Yale University School of Medicine. "This particular study provides one piece of the puzzle to help us understand this complicated signaling process. However, there are many pieces of the puzzles remaining to be found."

Aberrations in the mTOR signaling pathway have been implicated in cancer, cardiovascular disease, autoimmunity and metabolic disorders. They have also been identified in a phenomenon called the Warburg Effect, which allows cells to grow not only in nutrient-starved conditions but also in the oxygen-deprived environment typically found inside tumors.

A drug called rapamycin, which inhibits mTOR (in fact, its name is an acronym for Mammalian Target of Rapamycin), is being studied as a potential targeted drug for many forms of cancer. But the drug only acts against one of the forms of mTOR, which appears in two complexes: mTORC1 and mTORC2. "A drug that could inhibit both would be better," says Kun-Liang Guan, professor of pharmacology at the University of California at San Diego. "This research found how to get rid of DEPTOR, and maybe provided a way to keep DEPTOR, which would inhibit both."

Designing drugs that target mTOR's complex signaling pathway requires a deep understanding of the subtle molecular interactions that naturally govern the system so that pharmaceutical interventions tug in the right places at the right times. "The more you understand the whole," says Wei, "the better you can design drugs to alter it."

Contact: Bonnie Prescott
Beth Israel Deaconess Medical Center

Related medicine news :

1. A new set of building blocks for simple synthesis of complex molecules
2. 2-year-old children understand complex grammar
3. Complex choices in Medicare Advantage program may overwhelm seniors, study finds
4. Mimicking biological complexity, in a tiny particle
5. Complexities of Autism Extend to Its Treatment
6. Explosions Continue to Rock Japanese Nuclear Complex
7. Global view of blood cell development reveals new and complex circuitry
8. ICU communication study reveals complexities of family decision-making
9. The too many faces of war -- why the war in Afghanistan is so complex
10. Unlocking the secret of beauty: Scientists discover the complexities of attractive female bodies
11. Targeted therapy triggers complex mechanism of resistance
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology: